These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28292940)

  • 41. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
    Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
    Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.
    Boss DS; Witteveen PO; van der Sar J; Lolkema MP; Voest EE; Stockman PK; Ataman O; Wilson D; Das S; Schellens JH
    Ann Oncol; 2011 Feb; 22(2):431-7. PubMed ID: 20924078
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.
    Azzariti A; Bocci G; Porcelli L; Fioravanti A; Sini P; Simone GM; Quatrale AE; Chiarappa P; Mangia A; Sebastian S; Del Bufalo D; Del Tacca M; Paradiso A
    Br J Cancer; 2011 Mar; 104(5):769-80. PubMed ID: 21304529
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel therapeutic combination sequentially targeting aurora B and Bcl-xL in hepatocellular carcinoma.
    Matsunaga H; Tanaka S; Aihara A; Ogawa K; Matsumura S; Ban D; Ochiai T; Irie T; Kudo A; Nakamura N; Arii S; Tanabe M
    Ann Surg Oncol; 2015 Sep; 22(9):3079-86. PubMed ID: 25524010
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of Aurora-B kinase activity confers antitumor efficacy in preclinical mouse models of early and advanced gastrointestinal neoplasia.
    Alferez DG; Goodlad RA; Odedra R; Sini P; Crafter C; Ryan AJ; Wedge SR; Wright NA; Anderson E; Wilkinson RW
    Int J Oncol; 2012 Oct; 41(4):1475-85. PubMed ID: 22858681
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
    Aihara A; Tanaka S; Yasen M; Matsumura S; Mitsunori Y; Murakata A; Noguchi N; Kudo A; Nakamura N; Ito K; Arii S
    J Hepatol; 2010 Jan; 52(1):63-71. PubMed ID: 19913935
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152.
    Tao Y; Zhang P; Girdler F; Frascogna V; Castedo M; Bourhis J; Kroemer G; Deutsch E
    Oncogene; 2008 May; 27(23):3244-55. PubMed ID: 18084327
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.
    Liu W; Lu Y; Chai X; Liu X; Zhu T; Wu X; Fang Y; Liu X; Zhang X
    J Exp Clin Cancer Res; 2016 Nov; 35(1):183. PubMed ID: 27887633
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.
    Yang C; Boyson CA; Di Liberto M; Huang X; Hannah J; Dorn DC; Moore MA; Chen-Kiang S; Zhou P
    Cancer Res; 2015 May; 75(9):1838-45. PubMed ID: 25744718
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antitumor Effect of the Atypical Retinoid ST1926 in Acute Myeloid Leukemia and Nanoparticle Formulation Prolongs Lifespan and Reduces Tumor Burden of Xenograft Mice.
    El-Houjeiri L; Saad W; Hayar B; Aouad P; Tawil N; Abdel-Samad R; Hleihel R; Hamie M; Mancinelli A; Pisano C; El Hajj H; Darwiche N
    Mol Cancer Ther; 2017 Oct; 16(10):2047-2057. PubMed ID: 28619754
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Potential Contribution of microRNAs in Anti-cancer Effects of Aurora Kinase Inhibitor (AZD1152-HQPA).
    Zekri A; Mesbahi Y; Boustanipour E; Sadr Z; Ghaffari SH
    J Mol Neurosci; 2018 Aug; 65(4):444-455. PubMed ID: 30051358
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.
    Rahaman MH; Yu Y; Zhong L; Adams J; Lam F; Li P; Noll B; Milne R; Peng J; Wang S
    Invest New Drugs; 2019 Aug; 37(4):625-635. PubMed ID: 30194564
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
    Airiau K; Prouzet-Mauléon V; Rousseau B; Pigneux A; Jeanneteau M; Giraudon M; Allou K; Dubus P; Belloc F; Mahon FX
    Oncotarget; 2016 Jan; 7(1):845-59. PubMed ID: 26625317
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
    Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
    Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma.
    Wang S; Hwang EE; Guha R; O'Neill AF; Melong N; Veinotte CJ; Conway Saur A; Wuerthele K; Shen M; McKnight C; Alexe G; Lemieux ME; Wang A; Hughes E; Xu X; Boxer MB; Hall MD; Kung A; Berman JN; Davis MI; Stegmaier K; Crompton BD
    Clin Cancer Res; 2019 Jul; 25(14):4552-4566. PubMed ID: 30979745
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro.
    Tomita M; Tanaka Y; Mori N
    Int J Cancer; 2010 Oct; 127(7):1584-94. PubMed ID: 20091867
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity.
    Li J; Hu H; Lang Q; Zhang H; Huang Q; Wu Y; Yu L
    Eur J Med Chem; 2013 Jul; 65():151-7. PubMed ID: 23707920
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
    Keegan K; Li C; Li Z; Ma J; Ragains M; Coberly S; Hollenback D; Eksterowicz J; Liang L; Weidner M; Huard J; Wang X; Alba G; Orf J; Lo MC; Zhao S; Ngo R; Chen A; Liu L; Carlson T; Quéva C; McGee LR; Medina J; Kamb A; Wickramasinghe D; Dai K
    Mol Cancer Ther; 2014 Apr; 13(4):880-9. PubMed ID: 24526162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo.
    Weir MC; Shu ST; Patel RK; Hellwig S; Chen L; Tan L; Gray NS; Smithgall TE
    ACS Chem Biol; 2018 Jun; 13(6):1551-1559. PubMed ID: 29763550
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
    Evans RP; Naber C; Steffler T; Checkland T; Maxwell CA; Keats JJ; Belch AR; Pilarski LM; Lai R; Reiman T
    Br J Haematol; 2008 Feb; 140(3):295-302. PubMed ID: 18076711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.